

Additional Information from AstraZeneca

In anticipation of a possible decrease of the *SYMBICORT®(budesonide/fomoterol fumarate dihydrate) Inhalation Aerosol* WAC price in early January 2024, AstraZeneca has established a program aimed at mitigating the negative financial impact to PBA Health customers.

Specifically, PBA Health will administer a Price Adjustment Rebate (“PAR”) on behalf of AstraZeneca.

The following SYMBICORT NDCs are eligible for a PAR:

SYMBICORT 80/4.5MCG	00186-0372-20
SYMBICORT 160/4.5MCG	00186-0370-20

Assuming a WAC decrease takes effect on January 1, 2024 below are the key milestones associated with the PAR program.

- ▶ Following the WAC change, PBA Health will provide to AstraZeneca a report, by customer, of all SYMBICORT sales between December 20, 2023 and December 31, 2023 (“sales” includes orders that have been taken and committed to by PBA Health)
- ▶ AstraZeneca will validate the sales report for each customer and will extract certain ineligible sales according to the program’s established rebate eligibility rules:
 - Hospital Unit Dose NDCs (00186-0372-28 & 00186-070-28) are not eligible
 - 340B sales are not eligible
 - Certain sales made under AZ contracted pricing are not eligible
- ▶ AstraZeneca will calculate each customer’s PAR (validated sales multiplied by the difference between the “old” and “new” WAC)
- ▶ AstraZeneca will pay the rebates to PBA Health who will disperse the PAR to all customers no later than March 15, 2024

Returns:

A Symbicort specific exception to the AstraZeneca’s Expired Return Goods (ERG) Policy will be implemented. Future ERG claims for product sold prior to the effective date of a new lower price will be valued and credited at the new lower Price effective January 1, 2024 assuming all other terms of the AstraZeneca Return Good Policy have been met.